YY/T 1292.2-2015Test for reproductive and developmental toxicity of medical devices - Part 2: Prenatal developmental toxicity test (English PDF)
医疗器械生殖和发育毒性试验 第2部分:胚胎发育毒性试验
This is a limited preview
Buy now to download the full PDF (15 pages)
Need quotation for your management?
Get a formal quotation for YY/T 1292.2-2015 in 30 minutes.
Issued by
NMPA
Level / Type
Industry · Recommended
Issue date
March 2, 2015
Implementation date
January 1, 2016
Scope
YY/T 1292.2-2015 is the English-translated version of 医疗器械生殖和发育毒性试验 第2部分:胚胎发育毒性试验.
YY/T 1292.2-2015 is the Chinese pharmaceutical industry standard that gives the prenatal developmental toxicity test for a medical device or material, the embryo toxicity test of the series.
It is the second part of the YY/T 1292 series and sets out the pregnant animals and their exposure during organogenesis, the examination of the uterine contents, the observations on the fetuses and their skeleton and viscera and the interpretation of the findings. Issued on 2 March 2015, it has applied since 1 January 2016.
Found what you need?
Document preview — YY/T 1292.2-2015
National Standard of the People's Republic of China
- ICS
- 11.040.01
- Classification
- C 30
Issued by: National Medical Products Administration of the People's Republic of China
Contents
- Foreword
- Introduction
- 1 Scope
- 2 Normative references
- 3 Terms and Definitions
Foreword
YY/T 1292 "Medical Devices reproductive and developmental toxicity test" intended to divide part of the publication, currently plans to release The following components.
--- Part 1. Screening test;
--- Part 2. embryo toxicity test; This section YY/T 1292 Part 2. This section drafted in accordance with GB/T 1.1-2009 given rules.
Some elements of this document may involve patents. Release mechanism of the present document does not assume responsibility for the identification of these patents.
Introduction
Detect potential reproductive GB/T 16886.3 given and test methods for developmental toxicity substances are the Organization for Economic Cooperation and Development (OECD) method "chemical testing guidelines" set forth, but these methods are made for the development of chemical properties, but did not give details Test procedure, and therefore not suitable for the direct detection of medical devices or materials. The original part of the basic reference test method OECD414 Then, and according to the characteristics of medical devices or materials test methods were appropriate modifications, it provides detailed test procedure can be used as
GB/T 16886.3 to one standard method of reproductive and developmental toxicity test.
Reproductive medical devices or materials and developmental toxicity potential has a very important influence on human health. Especially for medical resorbable Devices containing leachables or medical devices. GB/T 16886.3 recommended the following medical devices or materials, in the absence of exclusion of reproductive and developmental toxicity Lower risk evidence, should be considered reproductive and developmental toxicity test.
a) with possible reproductive tissue or embryo (fetus) direct long-term or permanent contact devices (including resorbable or leachable substances, such as Silicone gel breast implants);
b) storage of medical devices.
This section provides the contact during pregnancy pregnancy maternal medical devices and general information on development of the embryo, the main effect is the parent Shall, death, fetal deformity or change evaluation. This section does not include the contents of functional defects.
Due to the limitations of the impact of the test sample preparation and test method validation, etc., in determining the embryonic developmental toxicity test Before, should take full account of GB/T 16886.1 and GB/T 16886.18 requirements. It should lead to embryonic development drug use in the evaluation of medical devices Basis of risk, based on the decision to be tested shall be demonstrated.
Of resorbable or leachable medical devices containing filter material, if there is in the absorption, metabolism, distribution and research sufficiently reliable data, or Medical devices or materials are identified in the extract all the ingredients were not embryonic developmental toxicity, no longer need to be tested. Medical devices After an acceptable biological risk assessment, such as the risk of embryonic development has been excluded, then no further testing.
1 Scope
This section YY/T 1292 specifies the medical device materials or methods of embryo toxicity test.
This section applies to medical devices or materials reproductive and developmental toxicity test.
2 Normative references
The following documents for the application of this document is essential. For dated references, only the dated version suitable for use herein Member. For undated references, the latest edition (including any amendments) applies to this document.
GB/T 16886.1 Biological evaluation of medical devices - Part 1. Evaluation of the risk management process and Test
GB/T 16886.2 Biological evaluation of medical devices - Part 2. Animal welfare requirements
GB/T 16886.3 Biological evaluation of medical devices - Part 3. Tests for genotoxicity, carcinogenicity and reproductive toxicity
GB/T 16886.12 Biological evaluation of medical devices - Part 12. Sample preparation and reference materials
3 Terms and Definitions
GB/T 16886.1, GB/T 16886.3 and GB/T 16886.12 defined and the following terms and definitions apply to this document.
3.1 Developmental Toxicology
Offspring before birth, perinatal exposure to sexual maturity or after the birth of the medical device body caused developmental toxicity. Including. machine Body of death, structural abnormalities, altered growth and functional defects. Developmental toxicology usually refers Teratology.
3.2 Altered growth
Offspring organ or body weight change in size.
3.3 Abnormalities (abnormal) alterations (anomalies)
During the development of structural abnormalities, including deformities and variations.
3.3.1 Malformation (main exception) malformation (majorabnormality)
Test animals are considered harmful structural changes (which may have fatal), usually rare.
3.3.2 Variation (small exception) variation (minorabnormality)
The test is considered less harmful or harmless animal structural changes; can be a transient appears and the control group, the frequency of occurrence is relatively high.
3.4 Conceptus
From the number of fertilized eggs after fertilization before delivery to the various development stages of the entire process derived, including membranes and the embryo or fetus.
......
This preview omits tables, figures, formulas and parts of the technical clauses. The complete document — 15 pages — is available in the English PDF.
Referenced standards
Normative references
- GB/T 16886.1Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
- GB/T 16886.2Biological evaluation of medical devices - Part 2: Animal welfare requirements
- GB/T 16886.3Biological evaluation of medical devices -- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
- GB/T 16886.12Biological evaluation of medical devices - Part 12: Sample preparation and reference materials
Similar standards
How to Download YY/T 1292.2-2015
- 1
Add to cart
Click "Download PDF" on this page and choose "Buy this standard". You can add more standards before checkout.
- 2
Checkout
Enter your email and billing details. Payment is processed securely by Stripe (cards or bank transfer). Prefer bank details? Request a quotation (min. order $300).
- 3
Instant delivery (0–9 sec)
Delivery is automatic: within seconds of payment you'll receive an email with a secure download link. The link stays valid for 72 hours.
- 4
Invoice included
A tax invoice is attached to the confirmation email. Need a custom invoice? Contact us.
Related Standards
GB/T 16886.1-2001 — Biological evaluation of medical devices - Part 1: Evaluation and testing
GB/T 16886.1-2011 — Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
GB/T 16886.1-2022 — Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
Secure payment via Stripe
Payments accepted
YY/T 1292.2-2015
$210.00